Consensus Elutia Inc.

Stocks

ELUT

US05479K1060

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-09-21 EDT			5-day change	1st Jan Change
0.8534 ^USD	+0.40%		+8.71%	+23.20%

08-17	Cellution Biologics Llc completed the acquisition of SimpliDerm human acellular dermal matrix business of Elutia Inc. for $11 million.	CI
08-13	Elutia Inc., Q2 2026 Earnings Call, Aug 13, 2026

Evolution of the Average Target: Elutia Inc.

Evolution of the Target Price: Elutia Inc.

Changes in Analyst Recommendations: Elutia Inc.

73e67a.JefO1NAtB3as1J3P1eyyT3wS_CdW5olfQr_nn1oHWCg.RLP4uZQfMUTIrNH7kavXeQpLyHMTqNobJdqgphVWYGkRuPqC_R5oMfm81A~e697f2a1c428651ea5da4a38403c76f8

Analysts' recommendations: Elutia Inc.

25-08-18	Cantor Fitzgerald Adjusts Elutia Price Target to $5 From $7, Maintains Overweight Rating	MT
24-06-21	Lake Street Adjusts Elutia Price Target to $10 From $5, Maintains Buy Rating	MT
24-06-20	Cantor Fitzgerald Adjusts Price Target on Elutia to $11 From $5, Maintains Overweight Rating	MT
23-11-14	Cantor Fitzgerald Cuts Elutia's Price Target to $6 From $8, Keeps Overweight Rating	MT
23-09-28	Lake Street Initiates Elutia at Buy Rating With $3 Price Target	MT
23-05-12	Cantor Fitzgerald Trims Price Target on Aziyo Biologics to $10 From $12, Maintains Overweight Rating	MT
22-11-16	Turist Securities Adjusts Aziyo Biologics Price Target to $10 From $8, Maintains Buy Rating	MT
22-11-15	Piper Sandler Adjusts Price Target on Aziyo Biologics to $10.50 From $9, Maintains Overweight Rating	MT
22-03-04	Cowen Adjusts Aziyo Biologics' Price Target to $13 From $15, Keeps Outperform Rating	MT
22-03-04	Piper Sandler Adjusts Aziyo Biologics' Price Target to $9 From $11, Reiterates Overweight Rating	MT
21-11-10	Piper Sandler Adjusts Aziyo Biologics' Price Target to $11 From $14, Reiterates Overweight Rating	MT
21-06-07	Aziyo Biologics : Piper Sandler Adjusts Aziyo Biologics PT to $14 From $20, Maintains Overweight Rating	MT
20-11-02	Aziyo Biologics : Cantor Fitzgerald Starts Aziyo Biologics at Overweight With $20 Price Target	MT
20-11-02	Aziyo Biologics : Cowen Starts Aziyo Biologics at Outperform With $20 Price Target	MT
20-11-02	Aziyo Biologics : Truist Securities Starts Aziyo Biologics at Buy With $20 Price Target	MT
20-11-02	Aziyo Biologics : Piper Sandler Starts Aziyo Biologics at Overweight With $20 Price Target	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELUTIA INC.			-	-	+488.24%
	REGENERON PHARMACEUTICALS, INC.					+8.21%
	MODERNA, INC.					-22.39%
	CSL LIMITED					+1.17%
	SAMSUNG BIOLOGICS CO.,LTD.					+40.74%
	UCB					+36.95%
	BIOGEN INC.					+10.53%
	INCYTE CORPORATION					+1.94%
	INNOVENT BIOLOGICS, INC.					+33.64%
	SWEDISH ORPHAN BIOVITRUM AB					+12.06%
	Average					+61.11%
	Weighted average by Cap.					+10.95%

See all sector performances

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

BUY

Number of Analysts

1

Last Close Price

0.8534USD

Average target price

5.000USD

Spread / Average Target

+485.89%

High Price Target

5.000USD

Spread / Highest target

+485.89%

Low Price Target

5.000USD

Spread / Lowest Target

+485.89%

Analyst Consensus Detail

Consensus revision (last 18 months)

Stock Market
Stocks
ELUT Stock
Consensus Elutia Inc.

-40%: Exceptional extension

SEIZE THE OFFER!